R.E.C.K vs Exparel in Robotic Nephrectomy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Planowana operacja usunięcia nerki wykonywana robotem chirurgicznym
- •Zdolność zrozumienia informacji o badaniu i chęć podpisania zgody
✗ Disqualifies
- •Ciąża
- •Stosowanie silnych leków na ból (opioidów) w ciągu ostatnich 30 dni
- •Alergia na R.E.C.K lub Exparel
- •Niestabilne problemy zdrowotne, takie jak aktywna infekcja, zaburzenia serca lub problemy psychiatryczne
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Levine Cancer
Charlotte, United States
Trial contact
Margarita Dzhanumova
Roy Ornob, MD
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.